Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Pyatyorochka has entered Yakutia

4/2/24 X5

EL5-Energo reported for 2023 by IFRS

4/2/24 ELFV

Astra reported for 2023 by IFRS

4/2/24 ASTR

Zaimer officially announced its intention to conduct an IPO

4/2/24 ZAYM

Novatek sharply reduced gas production at Arctic LNG-2

4/2/24 NVTK

Sollers reported for 2023 by RAS

4/2/24 SVAV

RBC reports for 2023 according by RAS

4/1/24 RBCM

MGTS reported for 2023 by RAS

4/1/24 MGTS

Forward Energy reported for 2023 by RAS

4/1/24 TGKJ

Chelyabinsk Forging and Pressing Plant reported for 2023 according by RAS

4/1/24 CHKZ